• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Axogen (AXGN) Is Back In The Spotlight, What Has Investors Looking Closer?

    Simply Wall St·10/09/2026 03:39:07
    Listen to the news

    Axogen (AXGN) has been drawing attention after recent price swings, with the share price at US$36.18 and a market value of about US$2.11b, putting the nerve repair specialist back on investor watchlists.

    Recent trading has been choppy for Axogen, with the 1-month share price return down 22.51% and the 7-day move also lower. However, the year-to-date share price return is up 16.71% and the 1-year total shareholder return is 120.34%, which indicates that longer term momentum remains stronger than the latest pullback suggests.

    Scan beyond Axogen and spot other health-focused stocks with sharp price moves and improving momentum using our curated list of 27 high quality undervalued stocks.

    After a 1-year total shareholder return above 100% and a sharp pullback in recent weeks, Axogen now sits at a crossroads. Does the current set up still tip the risk reward in favour of new buyers, or not?

    Most Popular Narrative: 32% Undervalued

    On Simply Wall St's most followed view, Axogen's fair value sits at $53.22 compared with the last close at $36.18, which puts a lot of weight on how the growth story plays out.

    Broad-based adoption of Axogen's nerve care algorithm across multiple markets (extremities, oral maxillofacial, breast) and exceptional momentum in activating high-potential accounts signal that the addressable market for nerve repair is still substantially underpenetrated, suggesting a long runway for sustained double-digit revenue growth as awareness and adoption rise.

    See why 8 investors see Axogen as 32% undervalued.

    Result: Fair Value of $53.22 (UNDERVALUED)

    Still, Axogen's reliance on Avance Nerve Graft and the uncertainty around the BLA process could quickly challenge this upbeat narrative if outcomes disappoint.

    Find out about the key risks to this Axogen narrative.

    Another View: What Axogen’s Price Says About Expectations

    The story looks very different once you focus on Axogen’s P/S ratio instead of fair value models tied to cash flows. The shares trade on P/S of 8.5x, compared with a fair ratio of 5.9x, a peer average of 8.2x and a broader US Medical Equipment industry level of 2.6x. That gap suggests investors are already paying a premium for Axogen’s growth profile. The key question is whether future execution will be strong enough to keep that premium in place or even expand it.

    For a closer look at how this premium could evolve as sentiment shifts around growth, profitability and risk, see the See what the numbers say about this price — find out in our valuation breakdown..

    NasdaqCM:AXGN P/S Ratio as at Oct 2026
    NasdaqCM:AXGN P/S Ratio as at Oct 2026

    Next Steps

    Feeling torn between Axogen’s recent gains and today’s volatility is natural. Move quickly from headline noise to the underlying numbers and weigh the balance of risks and rewards for yourself with 3 key rewards and 1 important warning sign.

    Looking For More Investment Ideas Beyond Axogen?

    If Axogen has your attention, do not stop there. Broaden your opportunity set with a few focused stock ideas built from different angles of quality and risk.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.